The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria
暂无分享,去创建一个
B. Ariff | N. Habib | H. Wasan | A. Al-nahhas | T. Barwick | I. Zerizer | A. Al-Nahhas | D. Towey | P. Tait | B. Ariff | H. Wasan | G. Hatice | N. Habib | T. Barwick | I. Zerizer | P. Tait | D. Towey | G. Hatice | A. Al-Nahhas | Harpreet Wasan | Nagy Habib | David Towey | Tara D. Barwick
[1] W. Weber. Positron emission tomography as an imaging biomarker. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] B. Nordlinger,et al. Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.
[3] Lawrence H Schwartz,et al. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] P. Flamen,et al. State of the art: radiolabeled microspheres treatment for liver malignancies , 2010, Expert opinion on pharmacotherapy.
[5] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[6] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[7] A. Maes,et al. FDG PET for monitoring response to local and locoregional therapy in HCC and liver metastases. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[8] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[9] I. Taylor,et al. The blood supply of colorectal liver metastases. , 1978, British Journal of Cancer.
[10] Annick D. Van den Abbeele,et al. The Lessons of GIST—PET and PET/CT: A New Paradigm for Imaging , 2008 .
[11] M Van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.
[12] Wolfgang A Weber,et al. Use of PET for monitoring cancer therapy and for predicting outcome. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] N. Habib,et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomography , 2007, Nuclear medicine communications.
[14] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. D. Van den Abbeele,et al. The Lessons of GIST — PET and PET / CT : A New Paradigm for Imaging , 2008 .
[16] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.
[17] S. Raman,et al. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[18] M. Okada,et al. [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.
[19] V. Goh,et al. Imaging tumor angiogenesis: functional assessment using MDCT or MRI? , 2006, Abdominal Imaging.
[20] T. Helmberger,et al. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors. , 2005, Cancer biotherapy & radiopharmaceuticals.
[21] Haesun Choi,et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Salem,et al. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.